Site Editor
Sandy Srinivas, MD
Sandy Srinivas, MD
Posted: Tuesday, March 26, 2024
Steven Raman, MD, FSAR, FSIR, of the David Geffen School of Medicine at the University of California, and colleagues reported on the 5-year outcomes of MRI-guided transurethral ultrasound ablation (TULSA) during the 2024 Society of Interventional Radiology (SIR) Annual Meeting (Abstract 135). The treatment demonstrated durable oncologic control, safety, and functional preservation after a single one-gland procedure.
“This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency. The success of TULSA represents a revolution in whole-gland treatment for prostate cancer,” said Dr. Raman in an SIR press release.
The study consisted of 115 men with Gleason grade 2 and 1 prostate cancer who received a single whole-gland TULSA treatment. They represented 13 sites in 5 countries. Of them, 21.7% received salvage treatment with surgery or radiation. After 1 year, cancer was undetectable on follow-up biopsy in 76%, and after 5 years, patients saw prostate volume reduced by 92% and PSA levels reduced from 6.3 ng/mL to 0.63 ng/mL. Grade 3 adverse events were reported in 10% of patients, with no grade 4 events observed. A total of 92% of patients also recovered continence, and 87% experienced preserved erectile function.
A randomized controlled study known as the CAPTAIN trial, which will compare TULSA with radical prostatectomy (ClinicalTrials.gov identifier NCT05027477), is currently recruiting.
Disclosure: No disclosure information for the study authors was provided.
2024 Society of Interventional Radiology Annual Meeting
JNCCN Spotlights
